NASDAQ:CRBP Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis $50.04 -0.73 (-1.44%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$48.45▼$52.0050-Day Range$48.01▼$61.5552-Week Range$3.03▼$61.90Volume250,047 shsAverage Volume511,392 shsMarket Capitalization$534.78 millionP/E RatioN/ADividend YieldN/APrice Target$77.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Corbus Pharmaceuticals alerts: Email Address Corbus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.14 Rating ScoreUpside/Downside55.2% Upside$77.67 Price TargetShort InterestBearish10.45% of Float Sold ShortDividend StrengthN/ASustainability-0.65Upright™ Environmental ScoreNews Sentiment0.30Based on 2 Articles This WeekInsider TradingSelling Shares$2.53 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.77) to ($5.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.08 out of 5 starsMedical Sector156th out of 910 stocksPharmaceutical Preparations Industry59th out of 426 stocks 4.6 Analyst's Opinion Consensus RatingCorbus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorbus Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Corbus Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.45% of the float of Corbus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorbus Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Corbus Pharmaceuticals has recently increased by 1.67%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCorbus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorbus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCorbus Pharmaceuticals has received a 73.92% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Corbus Pharmaceuticals is -0.65. Previous Next 1.3 News and Social Media Coverage News SentimentCorbus Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Corbus Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for CRBP on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corbus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,530,799.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Corbus Pharmaceuticals is held by insiders.Percentage Held by Institutions64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corbus Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Corbus Pharmaceuticals are expected to decrease in the coming year, from ($3.77) to ($5.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corbus Pharmaceuticals is -7.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corbus Pharmaceuticals is -7.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorbus Pharmaceuticals has a P/B Ratio of 4.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Corbus Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Corbus Pharmaceuticals Stock (NASDAQ:CRBP)Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Read More CRBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRBP Stock News HeadlinesSeptember 5 at 10:03 AM | finance.yahoo.comCorbus Pharmaceuticals to Present at the 2024 Cantor Global Health ConferenceAugust 29, 2024 | americanbankingnews.comCorbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Reaffirmed by Royal Bank of CanadaSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 28, 2024 | markets.businessinsider.comRBC Capital Remains a Buy on Corbus Pharmaceuticals (CRBP)August 27, 2024 | msn.comCorbus Pharmaceuticals Holdings, Inc. (CRBP): One of Oppenheimer’s Top Stock Picks For the Next 12 MonthsAugust 20, 2024 | globenewswire.comCorbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston KungAugust 17, 2024 | finance.yahoo.comCRBP Sep 2024 70.000 put (CRBP240920P00070000)August 12, 2024 | seekingalpha.comCorbus Pharmaceuticals: A Pause In The Rally LikelySeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 11, 2024 | finance.yahoo.comWith 59% ownership, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) boasts of strong institutional backingAugust 6, 2024 | globenewswire.comCorbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateJuly 30, 2024 | globenewswire.comCorbus Pharmaceuticals to Participate in Upcoming Investor Conferences in AugustJuly 22, 2024 | markets.businessinsider.comBuy Rating Affirmed: Corbus Pharmaceuticals’ Promising Drug Pipeline and Growth PotentialJune 30, 2024 | investorplace.comTreasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered YetJune 3, 2024 | seekingalpha.comCorbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025June 1, 2024 | globenewswire.comSYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024May 30, 2024 | globenewswire.comCorbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare ConferenceMay 23, 2024 | globenewswire.comUpdated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual MeetingSee More Headlines Receive CRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRBP CUSIPN/A CIK1595097 Webwww.corbuspharma.com Phone(617) 963-0100Fax617-663-6085Employees40Year Founded2009Price Target and Rating Average Stock Price Target$77.67 High Stock Price Target$88.00 Low Stock Price Target$46.00 Potential Upside/Downside+55.2%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($6.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-64.79% Return on Assets-40.87% Debt Debt-to-Equity RatioN/A Current Ratio6.18 Quick Ratio6.18 Sales & Book Value Annual Sales$880,000.00 Price / Sales607.70 Cash FlowN/A Price / Cash FlowN/A Book Value$10.42 per share Price / Book4.80Miscellaneous Outstanding Shares10,687,000Free Float10,260,000Market Cap$534.78 million OptionableOptionable Beta2.59 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Yuval Cohen Ph.D. (Age 49)CEO & Director Comp: $907.78kMr. Sean F. Moran CPA (Age 66)M.B.A., Chief Financial Officer Comp: $609.28kMs. Lindsey SmithHead of Corporate Communications & Patient AdvocacyMs. Christina BertschHead of Human ResourcesDr. Dominic Smethurst M.A. (Age 49)M.D., Chief Medical Officer Key CompetitorsOrgenesisNASDAQ:ORGSChembio DiagnosticsNASDAQ:CEMICG OncologyNASDAQ:CGONJanux TherapeuticsNASDAQ:JANXCatalyst PharmaceuticalsNASDAQ:CPRXView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Sold 485,082 shares on 8/19/2024Ownership: 2.026%Darwin Global Management Ltd.Bought 325,140 shares on 8/15/2024Ownership: 3.042%Millennium Management LLCSold 83,253 shares on 8/15/2024Ownership: 2.261%The Manufacturers Life Insurance Company Bought 10,604 shares on 8/15/2024Ownership: 0.198%HighVista Strategies LLCBought 38,793 shares on 8/14/2024Ownership: 0.363%View All Insider TransactionsView All Institutional Transactions CRBP Stock Analysis - Frequently Asked Questions How have CRBP shares performed this year? Corbus Pharmaceuticals' stock was trading at $6.04 at the beginning of the year. Since then, CRBP stock has increased by 728.5% and is now trading at $50.04. View the best growth stocks for 2024 here. How were Corbus Pharmaceuticals' earnings last quarter? Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $0.29. Who are Corbus Pharmaceuticals' major shareholders? Top institutional investors of Corbus Pharmaceuticals include Darwin Global Management Ltd. (3.04%), Millennium Management LLC (2.26%), Assenagon Asset Management S.A. (2.23%) and Point72 Asset Management L.P. (2.03%). Insiders that own company stock include Yuval Cohen, Sean F Moran and Craig Stuart Millian. View institutional ownership trends. How do I buy shares of Corbus Pharmaceuticals? Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Corbus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL) and Matinas BioPharma (MTNB). This page (NASDAQ:CRBP) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
